PropranonolÀÇ ¿ë·®¿¡ µû¸¥ ½Äµµ Á¤¸Æ·ù ÀçÃâÇ÷ ¿¹¹æ
Prevention of Variceal Rebleeding According to the Dose of Propranolol
´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 1È£ p.30 ~ p.32
ÀåÀ翵(Jang Jae-Young) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌ¿õö(Lee Woong-Chul) - ¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Esophageal variceal bleeding is a common complication of liver cirrhosis. Non-selective beta blockers (NSBB) have been established in numerous studies as one of the medical treatment for cirrhosis, especially in the primary and secondary prevention of variceal bleeding. The dose of NSBB is adjusted for a reduction in the resting heart rate by 25%, to 55 beat/min, or until the occurrence of adverse effect. The mean adjusted dose of propranolol in Korean study is 160 mg/day. Nevertheless, low dose propranolol is frequently used in real clinical field. A study by Kwon et al. showed that effect of propranolol in the prevention for esophageal rebleeding was superior in maximally-tolerable dose group of propranolol than low dose group. In this editorial, we have reviewed the studies of prevention for variceal rebleeding focusing on the dose of propranolol.
Å°¿öµå
Non-selective beta blocker, Liver cirrhosis, Esophageal varix, Rebleeding
KMID :
0882420140860010030
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)